EUVIMEDOpdag EUVIMED
Fallbericht

A Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib

Michael J Woodbury, Carly Grant, Lourdes Perez-Chada, Avery H LaChance, Joseph F Merola

Journal of Drugs in Dermatology · 2024-02-01 · 23 (2) · e60-e63

DOI: 10.36849/jdd.7645 ↗

At a glance

Fallbericht in Journal of Drugs in Dermatology, published online on 2024-01-01. Written by Michael J Woodbury and 4 co-authors. Major MEDLINE topics: Arthritis, Psoriatic, Heterocyclic Compounds, 3-Ring, Psoriasis, Tumor Necrosis Factor Inhibitors. Cited 13 times so far (Crossref).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Tumor necrosis factor-alpha inhibitors (TNF-i) are commonly used to treat immune-mediated diseases such as psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD), spondyloarthritis (SpA) and rheumatoid arthritis (RA). However, paradoxical psoriasis induced by TNF-i has been described and is not uncommon, particularly with infliximab and etanercept. The presentation of TNF-i-induced psoriasis is most commonly plaque or palmoplantar morphology. Optimal treatment strategies for recalcitrant psoriatic disease are not well understood. In this case series, we report three patients with TNF-i-induced psoriasis who were treated with upadacitinib and experienced complete resolution of their psoriatic eruptions. The efficacy of Janus kinase inhibitors (JAK-i) is possibly explained by mechanisms involving uncontrolled production of type 1 IFNs as well as increases in IL-23 and T-helper 17 cells upstream of relevant JAK/STAT pathways. We also offer a proposed treatment algorithm that includes the use of JAK-i as a promising management option in patients with recalcitrant disease. However, larger studies are needed to confirm the efficacy and safety of JAK-i in this patient population. J Drugs Dermatol. 2024;23(2): doi:10.36849/JDD.7645.

Subjects

MeSH terms (MEDLINE)

Arthritis, PsoriaticHeterocyclic Compounds, 3-RingPsoriasisTumor Necrosis Factor InhibitorsHumansAntibodies, Monoclonal

Substances

Antibodies, MonoclonalHeterocyclic Compounds, 3-RingTumor Necrosis Factor Inhibitorsupadacitinib

Cite

APA

Woodbury, M. J., Grant, C., Perez-Chada, L., LaChance, A. H., & Merola, J. F. (2024). A Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib. Journal of Drugs in Dermatology, 23(2), e60-e63. https://doi.org/10.36849/jdd.7645

Vancouver

Woodbury MJ, Grant C, Perez-Chada L, LaChance AH, Merola JF. A Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib. Journal of Drugs in Dermatology. 2024;23(2):e60-e63. doi:10.36849/jdd.7645

BibTeX
@article{Woodbury2024,
  author = {Woodbury, Michael J and Grant, Carly and Perez-Chada, Lourdes and LaChance, Avery H and Merola, Joseph F},
  title = {A Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  volume = {23},
  number = {2},
  pages = {e60--e63},
  doi = {10.36849/jdd.7645}
}
Start for free →